Bristol Myers Squibb Company $BMY Shares Newly Purchased by StoneRidge PMG Advisors LLC

StoneRidge PMG Advisors LLC bought a new stake in Bristol Myers Squibb Company (NYSE:BMY) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 8,668 shares of the biopharmaceutical company’s stock, valued at approximately $541,000.

Several other institutional investors also recently modified their holdings of the business. Davis Asset Management L.P. acquired a new position in Bristol Myers Squibb in the second quarter valued at approximately $27,000. Addison Advisors LLC bought a new position in Bristol Myers Squibb in the second quarter valued at approximately $32,000. Groupe la Francaise boosted its stake in Bristol Myers Squibb by 562.9% in the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 501 shares during the last quarter. Arlington Trust Co LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter worth $35,000. Finally, Kilter Group LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter worth $35,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Julia A. Haller sold 3,800 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total value of $240,578.00. Following the sale, the director directly owned 30,279 shares in the company, valued at $1,916,963.49. The trade was a 11.15% decrease in their position. The SEC filing for this sale provides additional information. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Stock Up 0.1%

Bristol Myers Squibb stock opened at $62.20 on Monday. The firm has a market capitalization of $127.15 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 0.32 and a beta of 0.20. The company’s 50 day simple moving average is $62.34 and its 200 day simple moving average is $60.11. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. Bristol Myers Squibb Company has a fifty-two week low of $45.26 and a fifty-two week high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.10 by $0.25. The firm had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The business’s quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.63 earnings per share. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.45 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were given a $0.63 dividend. The ex-dividend date was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is currently 55.88%.

Analyst Ratings Changes

Several analysts have commented on BMY shares. Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Raymond James Financial started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. HSBC reaffirmed a “hold” rating and set a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a research note on Thursday, September 10th. Wells Fargo & Company dropped their price objective on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, October 13th. Finally, Piper Sandler dropped their price objective on Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating for the company in a report on Monday, October 26th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb has an average rating of “Hold” and an average target price of $65.46.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.